186 related articles for article (PubMed ID: 28133938)
21. In vitro phase I metabolism of three phenethylamines 25D-NBOMe, 25E-NBOMe and 25N-NBOMe using microsomal and microbial models.
Grafinger KE; Stahl K; Wilke A; König S; Weinmann W
Drug Test Anal; 2018 Oct; 10(10):1607-1626. PubMed ID: 29971945
[TBL] [Abstract][Full Text] [Related]
22. Evolution of the NBOMes: 25C- and 25B- Sold as 25I-NBOMe.
Laskowski LK; Elbakoush F; Calvo J; Exantus-Bernard G; Fong J; Poklis JL; Poklis A; Nelson LS
J Med Toxicol; 2015 Jun; 11(2):237-41. PubMed ID: 25387562
[TBL] [Abstract][Full Text] [Related]
23. The electric Kool-Aid NBOMe test: LC-TOF/MS confirmed 2C-C-NBOMe (25C) intoxication at Burning Man.
Armenian P; Gerona RR
Am J Emerg Med; 2014 Nov; 32(11):1444.e3-5. PubMed ID: 24908444
[TBL] [Abstract][Full Text] [Related]
24. Characterization of the hepatic cytochrome P450 enzymes involved in the metabolism of 25I-NBOMe and 25I-NBOH.
Nielsen LM; Holm NB; Leth-Petersen S; Kristensen JL; Olsen L; Linnet K
Drug Test Anal; 2017 May; 9(5):671-679. PubMed ID: 27400739
[TBL] [Abstract][Full Text] [Related]
25. Test purchase, identification and synthesis of 2-amino-1-(4-bromo-2, 5-dimethoxyphenyl)ethan-1-one (bk-2C-B).
Power JD; Kavanagh P; O'Brien J; Barry M; Twamley B; Talbot B; Dowling G; Brandt SD
Drug Test Anal; 2015 Jun; 7(6):512-8. PubMed ID: 25078895
[TBL] [Abstract][Full Text] [Related]
26. Morbidity involving the hallucinogenic designer amines MDA and 2C-I.
Drees JC; Stone JA; Wu AH
J Forensic Sci; 2009 Nov; 54(6):1485-7. PubMed ID: 19878416
[TBL] [Abstract][Full Text] [Related]
27. Characterization of the designer drug bk-2C-B (2-amino-1-(bromo-dimethoxyphenyl)ethan-1-one) by gas chromatography/mass spectrometry without and with derivatization with 2,2,2-trichloroethyl chloroformate, liquid chromatography/high-resolution mass spectrometry, and nuclear magnetic resonance.
Frison G; Odoardi S; Frasson S; Sciarrone R; Ortar G; Romolo FS; Strano Rossi S
Rapid Commun Mass Spectrom; 2015 Jul; 29(13):1196-204. PubMed ID: 26395784
[TBL] [Abstract][Full Text] [Related]
28. Identification of substituted cathinones: 3,4-Methylenedioxy derivatives by high performance liquid chromatography-quadrupole time of flight mass spectrometry.
Fornal E
J Pharm Biomed Anal; 2013; 81-82():13-9. PubMed ID: 23603275
[TBL] [Abstract][Full Text] [Related]
29. Structural elucidation and identification of a new derivative of phenethylamine using quadrupole time-of-flight mass spectrometry.
Sekuła K; Zuba D
Rapid Commun Mass Spectrom; 2013 Sep; 27(18):2081-90. PubMed ID: 23943329
[TBL] [Abstract][Full Text] [Related]
30. Simultaneous analysis of 2Cs, 25-NBOHs, 25-NBOMes and LSD in seized exhibits using liquid chromatography-tandem mass spectrometry: A targeted approach.
Chia XWS; Ong MC; Yeo YYC; Ho YJ; Binte Ahmad Nasir EI; Tan LJ; Chua PY; Yap TWA; Lim JLW
Forensic Sci Int; 2019 Aug; 301():394-401. PubMed ID: 31234110
[TBL] [Abstract][Full Text] [Related]
31. NBOMe designer drug exposures reported to Texas poison centers.
Forrester MB
J Addict Dis; 2014; 33(3):196-201. PubMed ID: 25115175
[TBL] [Abstract][Full Text] [Related]
32. 2C-I-NBOMe, an "N-bomb" that kills with "Smiles". Toxicological and legislative aspects.
Nikolaou P; Papoutsis I; Stefanidou M; Spiliopoulou C; Athanaselis S
Drug Chem Toxicol; 2015 Jan; 38(1):113-9. PubMed ID: 24785196
[TBL] [Abstract][Full Text] [Related]
33. Structure fragmentation studies of ring-substituted N-trifluoroacetyl-N-benzylphenethylamines related to the NBOMe drugs.
Almalki AJ; Clark CR; DeRuiter J
Rapid Commun Mass Spectrom; 2020 Feb; 34(4):e8593. PubMed ID: 31518025
[TBL] [Abstract][Full Text] [Related]
34. Gas Chromatography Mass Spectrometry (GC-MS) for Identification of Designer Stimulants Including 2C Amines, NBOMe Compounds, and Cathinones in Urine.
Ketha H; Webb M; Clayton L; Li S
Curr Protoc Toxicol; 2017 Nov; 74():4.43.1-4.43.10. PubMed ID: 29117432
[TBL] [Abstract][Full Text] [Related]
35. Identification of Metabolite Biomarkers of the Designer Hallucinogen 25I-NBOMe in Mouse Hepatic Microsomal Preparations and Human Urine Samples Associated with Clinical Intoxication.
Poklis JL; Dempsey SK; Liu K; Ritter JK; Wolf C; Zhang S; Poklis A
J Anal Toxicol; 2015 Oct; 39(8):607-16. PubMed ID: 26378134
[TBL] [Abstract][Full Text] [Related]
36. Designer psychostimulants in urine by liquid chromatography-tandem mass spectrometry.
Kerrigan S; Mott A; Jatzlau B; Ortiz F; Perrella L; Martin S; Bryand K
J Forensic Sci; 2014 Jan; 59(1):175-83. PubMed ID: 24313279
[TBL] [Abstract][Full Text] [Related]
37. 2C-B: a new psychoactive phenylethylamine recently discovered in Ecstasy tablets sold on the Swiss black market.
Giroud C; Augsburger M; Rivier L; Mangin P; Sadeghipour F; Varesio E; Veuthey JL; Kamalaprija P
J Anal Toxicol; 1998 Sep; 22(5):345-54. PubMed ID: 9737327
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of use and acute toxicity associated with the use of NBOMe drugs.
Wood DM; Sedefov R; Cunningham A; Dargan PI
Clin Toxicol (Phila); 2015 Feb; 53(2):85-92. PubMed ID: 25658166
[TBL] [Abstract][Full Text] [Related]
39. 4-Bromo-2,5-dimethoxyphenethylamine (2C-B): a review of the public domain literature.
Cole MD; Lea C; Oxley N
Sci Justice; 2002; 42(4):223-4. PubMed ID: 12632938
[No Abstract] [Full Text] [Related]
40. Metabolic Profile Determination of NBOMe Compounds Using Human Liver Microsomes and Comparison with Findings in Authentic Human Blood and Urine.
Temporal KH; Scott KS; Mohr ALA; Logan BK
J Anal Toxicol; 2017 Sep; 41(7):646-657. PubMed ID: 28472358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
